Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) Files An 8-K Other Events

Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) Files An 8-K Other Events

Item 8.01.

Other Events

On November 16, 2016, Creative Medical Technology Holdings, Inc.
(the Company) issued a press release disclosing the creation of a
new subsidiary, AmnioStem LLC.

The press release furnished as Exhibit 99.1 to this Form 8-K may
contain forward-looking statements. Such forward-looking
statements are based on information presently available to the
registrants management and are current only as of the date made.
Actual results could also differ materially from those
anticipated as a result of a number of factors, including, but
not limited to, those discussed in the registrants Annual Report
on Form 10-K for the year ended December 31, 2015, and subsequent
reports filed by the Company with the Commission. For those
reasons, undue reliance should not be placed on any
forward-looking statement. The Company assumes no duty or
obligation to update or revise any forward-looking statement,
although it may do so from time to time as management believes is
warranted or as may be required by applicable securities law. Any
such updates or revisions may be made by the registrant by filing
reports with the Commission, through the issuance of press
releases or by other methods of public disclosure.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No. Description
99.1 Press Release dated November 16, 2016

About Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ)

Creative Medical Technology Holdings, Inc., formerly Jolley Marketing, Inc., operates through its subsidiary, Creative Medical Technologies, Inc. (CMT). The Company holds rights for infertility treatments, as well as the patent for its erectile dysfunction (ED) treatments. CMT is a development-stage enterprise and intends to complete the testing of its ED treatment. CMT is engaged in the regenerative medicine field of male and female sexual dysfunction and infertility using stem cells. CMT is engaged in an approximately 15-month clinical trial study being conducted by The Los Angeles Biomedical Research Institute on the efficacy and safety of the ED treatment, and markets treatment kits to physicians for use with their patients suffering from ED. The study involves testing on approximately 40 subjects. CMT also intends to test and market licensed stem cell products under its infertility technology license.

Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) Recent Trading Information

Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) closed its last trading session 00.000 at 0.510 with shares trading hands.

An ad to help with our costs